CNS Pharmaceuticals Maximum Drawdown
| CNSP Stock | | | USD 7.29 0.39 5.65% |
Maximum Drawdown (or MDD) is another indicator of risk. It is the reduction in asset value after a series of losing trades. This is normally calculated by getting the difference between a relative peaks in equity capital minus a relative trough. Below is CNS Pharmaceuticals's current Maximum Drawdown with peer comparisons and related risk metrics.
Current Maximum Drawdown Value
At 248.19, CNS Pharmaceuticals exhibits a severe peak-to-trough loss in Maximum Drawdown. CNS Pharmaceuticals's maximum drawdown exceeds 30%, reflecting significant downside exposure.
Maximum Drawdown | = | MAX(HIGH - LOW) |
| = | 248.19 | |
| MAX | = | Maximum notation for the range of returns on CNS Pharmaceuticals |
Maximum Drawdown Peers Comparison
Among sector peers, CNS Pharmaceuticals's Maximum Drawdown of 248.19 is above the 68.18 group average. The range runs from 22.24 (Pasithea Therapeutics Corp) to 150.0 (Windtree Therapeutics). CNS Pharmaceuticals's deeper drawdown relative to peers indicates greater historical downside exposure.
Maximum Drawdown Relative To Other Indicators
The chart below plots Maximum Drawdown against Maximum Drawdown for CNS Pharmaceuticals and its peers. Each point represents one equity — position along the horizontal axis shows Maximum Drawdown while the vertical axis shows Maximum Drawdown. Equities that cluster in different quadrants carry distinct risk-return profiles. Use the dropdowns to swap in other indicators for either axis.
CNS Pharmaceuticals's Maximum Drawdown reads
248.20 while Maximum Drawdown reads
248.20 , a
1.00 ratio between the two. The two measures are closely aligned in magnitude for CNS Pharmaceuticals.
Methodology, Assumptions & Data Sources
CNS Pharmaceuticals has a current Maximum Drawdown reading of 248.19. The Maximum Drawdown for CNS Pharmaceuticals applies a standardized calculation to daily closing prices and, where applicable, volume data across the selected period. The underlying data comes from exchange-reported daily closes with corporate action adjustments applied where relevant. CNS Pharmaceuticals operates in the health care sector, which may exhibit distinct volatility and momentum characteristics relative to the broader market. Indicator accuracy depends on data continuity across the calculation period. Gaps in trading history may affect the output.
Other Technical Indicators